%0 Journal Article
%T Prolonging Gastrointestinal-Stromal-Tumor-free life, an optimal suggestion of imatinib intervention ahead of operation
%A Chun-Jun Li
%A Jia Chen
%A Jian-Si Chen
%A Lin-Hai Yan
%A Wei-Zhong Tang
%A Yu-Zhou Qin
%A Zhi-Ning Chen
%J Journal of Cancer
%D 2018
%I Ivyspring International Publisher
%R 10.7150/jca.25263
%X Background: Imatinib has been regarded as the first successful synthetic small molecule targeting at blocking tyrosine kinase. Its high efficacy stabilized disease in above 80% of chronic myeloid leukemia (CML) patients over 10 years survival. Due to the similar canceration of gastrointestinal stromal tumor (GIST) as to CML, imatinib has been approved to be used as first-line treatment.
%K Gastrointestinal stromal tumor
%K Neoadjuvant imatinib
%K Surgical resection
%K Cancer-specific survival
%U http://www.jcancer.org/v09p3850.htm